XML 70 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 49 Months Ended
Aug. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
ft²
Jun. 30, 2018
USD ($)
€ / $
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
€ / $
Jun. 30, 2018
EUR (€)
Jun. 30, 2017
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2017
USD ($)
Commitments And Contingencies [Line Items]                  
License agreement commencement date         2006-03 2006-03      
Annual minimum payments for licenses     $ 4,104,000 $ 2,914,000 $ 9,908,000   $ 8,104,000    
Exchange rate relating to license payment | € / $     1.16801   1.16801        
Future minimum payments associated with license     $ 2,200,000   $ 2,200,000        
Rent expense related to operating leases     200,000 $ 100,000 400,000   $ 200,000    
Amount deposited into restricted cash account     350,000   350,000        
Acquired in-process research and development     7,888,000   7,888,000        
Other long-term liabilities     5,681,000   5,681,000       $ 1,938,000
Eden Prairie Minnesota [Member]                  
Commitments And Contingencies [Line Items]                  
Square feet facility | ft²   36,000              
Contractual obligations   $ 4,000,000              
Operating lease agreement term   10 years              
Operating lease agreement commencement date   2018-05              
Amount deposited into restricted cash account   $ 400,000              
License [Member]                  
Commitments And Contingencies [Line Items]                  
Annual minimum payments for licenses         $ 234,000 € 200,000      
Patents [Member]                  
Commitments And Contingencies [Line Items]                  
Patent expiry date         2027-09 2027-09      
Intellectual Property [Member] | Embolitech LLC [Member]                  
Commitments And Contingencies [Line Items]                  
Payments to acquire intellectual property assets     4,500,000            
Installment payment beginning period         2019-12 2019-12      
Installment payment ending period         2023-12 2023-12      
Contingent payments upon achievement of regulatory milestones         $ 2,000,000        
Contingency period ending year         2033 2033      
Acquired in-process research and development     7,900,000   $ 7,900,000        
Other current liabilities     500,000   500,000        
Other long-term liabilities     2,900,000   2,900,000        
Intellectual Property [Member] | Embolitech LLC [Member] | Scenario Forecast [Member]                  
Commitments And Contingencies [Line Items]                  
Estimated additional payment to acquire intellectual property assets $ 500,000             $ 3,500,000  
Selling, general and administrative [Member]                  
Commitments And Contingencies [Line Items]                  
Claim accrual recorded in selling, general and other administrative expenses         1,000,000        
Other Accrued Liabilities [Member]                  
Commitments And Contingencies [Line Items]                  
Claim accrual recorded in other accrued liabilities     $ 1,000,000   $ 1,000,000